Pain Management Devices Market Size, Share & Trends Analysis Report By Product (RFA, Neurostimulation), By Application (Neuropathic Pain, Cancer), By Region (APAC, North America), And Segment Forecasts, 2022 - 2030

Report Overview

The global pain management devices market size was valued at USD 6.40 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 9.3% from 2022 to 2030. The increasing prevalence of chronic diseases is one of the key factors expected to contribute to the market growth over the forecast period. The growing prevalence of lifestyle disorders, such as obesity and diabetes, has increased the demand for muscle and nerve stimulators. The growing prevalence of trauma or hypertension is another major factor likely to drive the market growth. Hypertension significantly increases the risk of a brain aneurysm and other chronic diseases. According to the WHO, Canada recorded the highest hypertension treatment rate of 76% in men and 71% in women in 2019.

The COVID-19 outbreak caused due to SARS-CoV-2, already affected millions of people globally. The contagious coronavirus is also having an economic impact and implications on most sectors including the medical device industry. The nationwide lockdown has impacted patients who specifically relied on exercise programs or PT as a pain management regimen. Moreover, many elective procedures and in-person patient visits have been suspended or delayed, which is expected to increase the demand for pain treatment at home. In April 2020, Omron launched the new Focus TENS Therapy device for the knee to its existing lineup of drug-free pain management products. The rising cancer cases are expected to further boost the demand over the forecast period.

Moreover, cases of musculoskeletal disorders, such as arthritis, osteoarthritis, orthopedic degenerative disorders, and rheumatoid arthritis, are increasing at a significant rate. This has augmented the prevalence of chronic pain in these individuals and the inability to carry out routine tasks. For instance, according to the CDC, over 24.5% of adults in the U.S. were suffering from arthritis in 2020, making this the primary reason for work disability. This has fueled the demand for pain management stimulators to manage chronic pain. Apart from this, in the year 2020, approximately 32.5 million people in the U.S. suffered from osteoarthritis.

The ineffectiveness of oral drugs is boosting patients to look for alternative treatment options, such as pain management devices. Several people are addicted to pain killers, however, these medicines are sometimes ineffective and cause various adverse effects. Moreover, the lack of preference for surgeries is one of the factors boosting the demand. According to the 2021 report by the CDC, there were around 1,57,500 surgical site infections reported every year in the U.S. The high hospitalization costs have increased the need for a reduced hospital stay and the need to shift to less expensive care settings, thus boosting demand.

For instance, the average hospital stay cost accounted for around USD 15,734 in 2018. Moreover, technological advancements are anticipated to drive the market further. For instance, in September 2020, Boston Scientific launched WaveWriter Alpha Spinal Cord Stimulator Systems for personalized pain relief, in Europe. This would significantly expand the company’s portfolio. In February 2022, Boston Scientific Corp. closed the acquisition of Baylis Medical Company, Inc.

This acquisition expanded Boston Scientific’s structural heart and electrophysiology product portfolios and included the radiofrequency NRG and VersaCross Transseptal Platforms and dilators used to support left heart access. Moreover, an increase in the number of bone-related disorders, accident cases, obesity, and the convenience of advanced designs are also expected to boost the market growth. Obesity is also the main cause of arthritis. According to studies published in the BMJ Journal in 2020, being overweight or obese increased the risk of knee OA by 2.5 to 4.6 times compared to being of normal weight.

Product Insights

On the basis of products, the market has been segmented into electrical stimulators, Radiofrequency Ablation (RFA), analgesic infusion pumps, and neurostimulation. The neurostimulation segment accounted for the largest share of more than 57.5% in 2021. The growth can be attributed to the increase in the prevalence of neurological disorders. These neurostimulators play a crucial role in treating chronic pain, Parkinson’s disease, epilepsy, movement disorders, and depression. In addition, certain factors like the introduction of technologically advanced products, rising product demand, and the growing geriatric population are anticipated to drive the market. For example, according to the U.K. government, the number of people within the age group of 60-64 years increased from 3,673 thousand in 2018 to 3,974 thousand in 2021.

Similarly, the population within the age group of 70-74 years increased from 3,252 in 2018 to 3,390 in 2021. Thus, the increasing geriatric population is likely to fuel the market growth this demographic is at a greater risk of chronic illness. The RFA segment is expected to register the fastest CAGR over the forecast period owing to its wide application scope in pain management, surgical oncology, gynecology, cardiology & cardiac rhythm management, and cosmetology. Radiofrequency ablation treatment is more beneficial in treating patients with multiple tumors than treating the patients via open surgery, thus fueling the segment growth. For instance, in June 2020, Boston Scientific launched a tool to monitor the effect of radiofrequency energy delivery during cardiac ablation procedures called DIRECTSENSE.

Application Insights

On basis of application, the market is segmented into cancer, neuropathic pain, facial & migraine, musculoskeletal disorder, trauma, and others. The neuropathic pain segment dominated the market with a revenue share of more than 31.5% in 2021. The growth can be attributed to the growing prevalence of the target population and increasing initiatives by the industry players. According to the U.S. Centers for Disease Control and Prevention, in 2019, 65% of Americans aged 65 years or above suffered from chronic pain. In addition, neuropathic pain affects 3% to 17% of adults. The aforementioned factors are expected to propel the segment growth.

The cancer segment is expected to register the fastest CAGR over the forecast period. The rising cancer cases have led to an increase in the product demand to reduce the pain caused by nerve compression mainly because of the tumor compressing and other variables depending upon cancer’s progression. Moreover, the growing prevalence of genetic diseases, such as Acute Lymphoblastic Leukemia (ALL), is also expected to drive market growth during the forecast period. According to a report published by the National Cancer Institute, an estimated 5,690 new cases of ALL and an estimated 1,580 deaths were recorded in 2021.

Regional Insights

North America accounted for the largest revenue share of more than 46.00% in 2021 owing to the favorable healthcare infrastructure, which facilitates easy access to advanced pain management devices. Moreover, increasing government initiatives, such as the Precision Medicine and Affordable Care Act, along with a well-planned reimbursement scenario in this region is contributing to the market growth. The regional market is also driven by the presence of well-established healthcare facilities, a growing aging population, and a high incidence of hypertension & stroke. With an increase in the elderly population, the market is expected to show a higher growth rate, as the aging population is at greater risk of chronic illness.

According to an NCBI publication, the prevalence of cerebral aneurysms in 2020 is approximately 3.2%, with a mean age of 50 years and an overall 1:1 gender ratio. Furthermore, the presence of key players in this region is also expected to drive market growth. These players include Baxter International Inc., Boston Scientific Corp., Medtronic, Abbott, Stryker Corp., and others. These players are involved in many strategic initiatives for growth in the market. For instance, in May 2019, Abbott partnered with the U.S. National Institutes of Health (NIH) for the development of unique insights and driving applications of various neuromodulation therapies.

The market in Asia Pacific is anticipated to grow at the fastest car during the forecast period. This growth can be attributed to R&D investments to produce technologically advanced healthcare treatment options. Moreover, the presence of several trade agreements is increasing the chances for market growth in the region. For instance, the Asia Pacific Trade Agreement (APTA) between China, Bangladesh, India, Lao PDR, Republic of Korea, Mongolia, and Sri Lanka has promoted trade liberalization and widened import and export opportunities amongst participating nations.

Key Companies & Market Share Insights

The market players are constantly involved in strategic initiatives, such as technology innovation, partnership, regional expansion, and mergers & acquisitions, to gain deeper penetration. For instance, in August 2020, Medtronic announced the commercial launch of its FDA-approved neurostimulator, called the InterStim Micro Neurostimulator. The implant was meant for Sacral Neuromodulation (SNM) therapy to help patients gain effective bladder and bowel control. In October 2020, Smiths Medical launched the CADD Solis ambulatory infusion pump’s new version 4.2. This wireless bi-directional communication pump would help integrate pain management data with EMR records of the patient. Some of the prominent key players in the global pain management devices market include:

• B Braun Melsungen AG

• Baxter

• Boston Scientific Corp.

• Nevro Corp.

• Enovis

• OMRON Healthcare, Inc.

• Medtronic

• ICU Medical, Inc.

• Abbott

• Stryker

• Stimwave LLC

Pain Management Devices Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For the purpose of this study, Grand View Research has segmented the global pain management devices market report on the basis of product, application, and region:

• Product Outlook (Revenue, USD Million, 2017 - 2030)

  • Electrical Stimulators

    • TENS

    • Others

  • Radiofrequency Ablation (RFA)

  • Analgesic Infusion Pumps

    • Intrathecal Infusion Pumps

    • External Infusion Pumps

  • Neurostimulation

    • Spinal Cord Stimulators

    • Deep Brain Stimulators

    • Sacral Neurostimulators

    • Others

• Application Outlook (Revenue, USD Million, 2017 - 2030)

  • Cancer

  • Neuropathic Pain

  • Facial & Migraine

  • Musculoskeletal Disorder

  • Trauma

  • Others

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Netherlands

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia